All company sites ABOUT COMPANY PRESS CENTER DIRECTIONS PRODUCTS INVESTORS 03.10 The child-savior saved his sister from a fatal hereditary disease. A unique operation was performed in Russia for the first time The child-savior saved his sister from a fatal hereditary disease. A unique operation was performed in Russia for the first time. 28.09 3 million patients with ischemia of the extremities in the Russian Federation need the help of cardiovascular specialists Russian experts conducted a statistical study to assess the prevalence of lower limb ischemia in Russia among the adult population. All news HUMAN STEM CELL INSTITUTE (PJSC "HSCI") The Human Stem Cell Institute (HSCI PJSC) is a Russian public biotechnology company founded in 2003. HSCI's areas of activity are development, commercialization, and further promotion on the market of its own innovative medicines and high-tech services in the field of regenerative medicine, medical genetics (including reproductive), gene therapy, bioinsurance and biopharmaceuticals. The company aims to create a new culture of medical care for a person - the development of healthcare in the field of personalized and preventive medicine. HSCI owns the bank for personal storage of cord blood stem cells Gemabank ® - the largest in the Russian Federation and the CIS, as well as the bank of human reproductive cells - Reprobank ® (personal storage and donation). The company brought to the market the first Russian gene therapy drug for the treatment of lower limb ischemia of atherosclerotic genesis - Neovasculgen ® , as well as an innovative medical technology for the use of dermal autofibroblasts to restore skin with signs of age and other structural changes - SPRS-therapy ® . HSCI is implementing a socially significant project Genetico ® to provide genetic diagnostics and counseling services for the early detection and prevention of hereditary diseases, as well as pathologies with a genetic component, incl. in the reproductive sphere (including DNA screening, diagnostic panels for certain categories and cases of diseases, preimplantation genetic diagnostics , non-invasive prenatal research , services in the field of oncogenetics and bioinformatics ). Since 2013, the range of genetic diagnostics and counseling services has been provided on the basis of a new laboratory and production complex created by HSCI in Moscow. The company aims to develop its products in the Russian and world markets. PJSC HSCI is the issuer of the RII sector of the Moscow Exchange (ticker: ISKJ ). HSCI's initial public offering in December 2009 was the first IPO of a biotech company in Russia. Disclaimer List of insider information © 2003-2016 Human Stem Cell Institute Information disclosure of PJSC "HSCI" on the website of LLC "Interfax-TsRKI"